Gedeon Richter's Progressive Medical Approach for Endometriosis Treatment

On April 24-26, 2025, an important event took place in Prague that focused on a persistent and chronic condition affecting millions of women worldwide: endometriosis. The SEUD Congress, organized by the Society of Endometriosis and Uterine Disorders, gathered leading experts to discuss modern medical treatments and share the latest advancements in managing this condition.

Endometriosis affects over 190 million women globally and is characterized by tissue similar to the uterus lining growing outside the uterus cavity. This can lead to significant inflammation, scarring, and pain. Remarkably, many women experience an average of 7 to 9 years before receiving a proper diagnosis and treatment, highlighting a critical delay in care. The chronic pain associated with endometriosis can severely impact a woman's quality of life and fertility.

Historically, surgery was the primary recourse for dealing with endometriosis. However, medical therapy has emerged as a preferred option due to its effectiveness and lower invasiveness. Gedeon Richter, a major player in women's health pharmaceutical solutions, showcased their pioneering combined therapy involving GnRH (gonadotropin-releasing hormone) antagonists to treat symptomatic endometriosis and uterine fibroids.

Patients benefit from this unique combination which works efficiently to alleviate symptoms without the need for surgical intervention. Clinical trials have shown a significant percentage of women treated with hormonal therapies achieve reduced pain and an enhanced quality of life, with reported improvements in over 70% of cases.

Among the revered speakers at the conference, Professor Charles Chapron from France, Dr. Harald Krentel from Germany, Dr. Stavros Karampelas from Belgium, and Dr. Silvia Vannuccini from Italy discussed the vital need for modern approaches in treating this complex condition. They emphasized that medical professionals are moving towards patient-centric methodologies, focusing on tailored care that not only addresses physical symptoms but also contributes positively to the overall well-being of patients.

Péter Turek, from Gedeon Richter’s women’s healthcare division, asserted that their commitment is to offer innovative solutions that resonate globally. For women affected by endometriosis, having access to contemporary therapies is crucial for a better quality of life. As advancements continue, the aim is to control symptoms effectively while minimizing the need for invasive surgical procedures.

Notably, surgery, although sometimes necessary in severe cases, carries risks such as a 30-50% chance of symptom recurrence within five years. Gedeon Richter's pharmacological treatments present a safer, long-term alternative for managing endometriosis while enabling women to protect their health and fertility.

The prospects for women living with endometriosis are changing for the better. With innovative therapeutic options available, managing symptoms without invasive procedures is becoming a reality. This shift empowers women, allowing them to reclaim their lives from the shackles of chronic pain.

As the congress wrapped up, it left attendees with a sense of hope for the future of endometriosis treatment. The emphasis on using progressive medical therapies reinforces the importance of continuous advancement in women's health, ensuring millions of women receive the care they need to live more fulfilling lives.